Skip to content

The Long-term Impact of Invasive Meningococcal Disease in Australian Adolescents and Young Adults

The Long-term Impact of Invasive Meningococcal Disease in Australian Adolescents and Young Adults

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03798574
Acronym
AMEND
Enrollment
98
Registered
2019-01-10
Start date
2016-03-01
Completion date
2022-12-31
Last updated
2023-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Meningococcal Infections, Neisseria Infection, Neisseria Meningitis Sepsis

Brief summary

Survivors of invasive meningococcal disease (IMD) experience a range of mild to severe sequelae that impact upon their quality of life. The majority of studies to date have focused on the impact of IMD on childhood and very little is known about the impact of the disease on adolescents and young people. The aim of this study is to assess the physical, neurocognitive, economic and societal impact of IMD on adolescents and young adult Australian survivors. Hypothesis: 1. Adolescents and young adult survivors who are 2 to 10 years post IMD have significantly poorer outcomes including intellectual functioning and quality of life when compared to healthy controls. 2. IMD imposes a significant financial burden upon individuals, families and society. 3. Serogroup B disease is associated with an increased risk of sequelae when compared to non-B serogroup IMD. Study design: This a multi-centre, case-control mixed-methods study. Survivors of IMD (retrospective and prospective cases) and non-IMD healthy controls will be invited to participate in the study. Retrospective IMD cases admitted in the previous 10 years will be identified through each of the participating hospitals (paediatric and adult hospitals). During the course of the study prospective recruitment of IMD cases will also occur at participating hospitals. Meningococcal foundations/groups will also be approached and asked to advertise and conduct a mail out to their members to inform them about the study. Healthy controls will be prospectively recruited by snowballing technique whereby enrolled IMD cases will be asked to distribute a study information sheet to their healthy friends/acquaintances who are approximately the same age. Control participants may also be identified from databases at each participating site or through community advertising. Enrolled cases will undergo a neurocognitive, psychological and physical examination 2 - 10 years post IMD admission. A subset of IMD cases will be invited to participate in a semi-structured interview. Controls will also undergo neurocognitive, psychological and physical examination.

Interventions

None listed

Sponsors

University of Adelaide
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
15 Years to 24 Years
Healthy volunteers
Yes

Inclusion criteria

* Patients aged 15 to 24 years 11 months at time of IMD admission * Hospitalised IMD case from 1st January 2006 -with serogroup B or non-B IMD, confirmed by culture or polymerase chain reaction (PCR) in blood or CSF. * Healthy controls aged 17 to 34 years 11 months at the time of assessment.

Exclusion criteria

* Individuals who are not fluent with the English language. * Control participants with a history of meningitis, encephalitis, or meningococcal disease, intellectual disability, intracranial pathology (eg. traumatic brain injury) that may impact on cognitive functioning, or significant vision and/or hearing loss that may impact on the validity or reliability of the neurocognitive assessment.

Design outcomes

Primary

MeasureTime frameDescription
Difference in intellectual functioning between cases and controlsBetween 2 to 10 years post IMD admissionMeasured by the Full Scale intelligence quotient (IQ) score obtained from the Wechsler Adult Intelligence Scale - Fourth Edition (WAIS-IV)
Difference in quality of life between cases and controlsBetween 2 to 10 years post IMD admissionMeasured by the overall multi-attribute health utility score obtained from the Health Utilities Index Mark 3 (HUI3)-15Q self-report.

Secondary

MeasureTime frameDescription
Difference in executive functioning between cases and controls.Between 2 to 10 years post IMD admissionMeasured by Delis-Kaplan Executive Function System (D-KEFS)
Difference in executive functioning between cases and controls assessed through BRIEF self-report questionnaireBetween 2 to 10 years post IMD admissionAssessed through BRIEF self-report questionnaire (parent and/or self-report)
Difference in the frequency of psychiatric disorders between cases and controls.Between 2 to 10 years post IMD admissionAssessed through Mini International Neuropsychiatric Interview (M.I.N.I 6.0)
Difference in psychological functioning between cases and controls.Between 2 to 10 years post IMD admissionAssessed through self report questionnaire Depression Anxiety Stress Scales (DASS) (self-report)
Difference in behavioral ratings between cases and controlsBetween 2 to 10 years post IMD admissionMeasured by Conners Rating Scales (parent and/or self-report)
Difference in health and disability functioning between cases and controlsBetween 2 to 10 years post IMD admissionMeasured by the International Classification of Functioning, Disability and Health (ICF) tool.
Difference in academic achievement between cases and controls.Between 2 to 10 years post IMD admissionMeasured by Wechsler Individual Achievement Test - Second Edition (WIAT-II)
Difference in health status between cases and controlsBetween 2 to 10 years post IMD admissionThe EQ-5D-5L will be completed to measure participant's health status and to calculate quality adjusted life years (QALYS) lost.
To estimate the lifetime costs associated with survival following IMDFrom time of admission up to time of follow up (2 to 10 years post IMD admission)IMD cases only: Lifetime dollar costs.
Explore adolescents and young people's experience of their hospital presentation, admission, and recovery from IMDBetween 2 to 10 years post IMD admissionA subset of IMD cases will participate in a semi-structured interview.
Carer's experience assessed through the Carer Experience ScaleBetween 2 to 10 years post IMD admissionFor those IMD cases with a disability, the primary caregiver and other family members living in the same household will be invited to complete the Carer Experience Scale.
Carer's experience assessed through ICEpop CAPability questionnairesBetween 2 to 10 years post IMD admissionFor those IMD cases with a disability, the primary caregiver and other family members living in the same household will be invited to complete ICEpop CAPability questionnaire.
Difference in hearing threshold levels between cases and controlsBetween 2 to 10 years post IMD admissionMeasured by pure tone audiometry.
Difference in memory (verbal and visual) between cases and controls.Between 2 to 10 years post IMD admissionMeasured by Verbal Learning and Design Memory subtests from the Wide Range Assessment of Memory and Learning, Second Edition (WRAML2)

Countries

Australia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 20, 2026